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ABSTRACT
A number of transition metals and their terpyridyl complexes have been evaluated for antimalarial activity on the strain 3D7. The
metals, ligands and complexes were each in turn investigated for their efficacy. All activities were in the sub-micromolar range
(0.1–1 µM). Their modes of action were compared with that of chloroquine to discover whether or not they were capable of inhibit-
ing haemozoin formation. The data indicate that efficacy could be a result of several mechanisms and that speciation of the metal
complex and the manner in which the agents are added to the parasitic broth have a profound effect on the activity of the agents.
We believe that our study offers a template by which other researchers should approach their experiments using transition metal
complex agents.
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1. Introduction
As of 2004 malaria was endemic in 107 countries with approxi-
mately 3.2 billion people exposed to infection. It is estimated that
between 300 and 500 million clinical cases occur per year, caused
primarily by Plasmodium falciparum and Plasmodium vivax.
Plasmodium falciparum is directly responsible for more than one
million deaths (mostly African children under the age of five)
annually, and may contribute to even more deaths in combina-
tion with other illnesses. More than 80 % of these deaths take
place in sub-Saharan Africa. The mortality effect of malaria in
Africa is amplified by the high rate of HIV/AIDS infections as
well as the inability of public health systems to deal with such
high infection rates.1
The transportation and accumulation of metal ions into the
malaria parasite is one aspect of the parasite which is of particular
interest as a potential drug target.2 While a significant amount
of work has been performed on the transport and uptake of
organic solutes, there has in contrast been very little research on
the parasites preference for metals, especially for the transition
metals of copper, iron, gold and platinum. For copper and iron
there is some, though little, research on the parasites require-
ment for these metals. Due to the trace amounts of gold and
platinum in the human body it is not surprising that there is no
report of the infected red blood cells’ (iRBCs) ability to transport
these metals.
It has been shown that during the parasite’s life cycle it has no
need to accumulate copper, since the amounts present within
the RBC prior to invasion are sufficient to support the parasite.3
It was even reported that the parasite demonstrates pathways
which in fact remove copper from the infected erythrocyte,
leaving the infected blood cell with approximately 66 % of the
average amount found in a normal erythrocyte.3 Thus it appears
that the parasite has an efficient copper efflux system to remove
the toxic metal which is freed during the degradation of erythro-
cyte proteins.4 In the case of iron there has been evidence to both
suggest and refute that the parasite obtains this element from
the serum, from the erythrocyte as free iron or from degraded
haemoglobin. Reports in favour of transport from the serum,
show evidence for transferrin-independent iron translocation5
and the resistance to malaria that people suffering from anaemia
have demonstrated.6,7 Arguments against the serum as a source
of iron stem from the lack of transferrin receptors on iRBC
membranes,8 that iron-supplemented diets had no effect on the
course of malaria in infected patients9 and that there was a
minimal increase in the uptake of radiolabelled iron in iRBCs
when compared with normal RBCs.10 In one study iron seques-
tration agents were preloaded into erythrocytes and shown to
have little or no effect on the invading species activity suggest-
ing that free erythrocytic iron may not be required by the para-
site.11 Haemoglobin degradation might seem an obvious source
of this metal;12 it has been demonstrated by Egan et al. that 95 %
of the parasite-digested haem iron can be found in haemozoin.
The parasites source of iron is thus disputed. Scheibel et al.
did, however, also prove that transport of this metal ion, and
presumably others, such as copper, gold and platinum, can
be mediated by ligands such as 8-hydroxyquinoline (uptake
of serum iron increased from 9 % to 50 % in the presence of
8-hydroxyquinoline).9
Surprisingly, the general approach to the application of metal
‘complexes’ in malarial experiments is not uniform. Not only
have researchers not tested the background activity of the
metals but also on many occasions the metal ion and ligand were
added as a ‘cocktail’ solution with the expectation that a complex
will form. The exact ratio of metal to ligand and thereby the
active species is thus indiscernible.
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What little research there is on the transport of metal ions
(perhaps with the exception of sodium and calcium) into the
infected erythrocyte, suggests that in general transportation of
metals into the parasite is likely to be mediated by organic ligands.
In light of the paucity of literature studies on their antimalarial
activity, it was decided to examine the activity of these metals
using a ligand whereby the corresponding metal complexes
are water soluble under biological conditions. Only on a single
occasion have some terpyridyl (1) derivative complexes been
tested for their antimalarial activities in a patent released by
Lowe.13 However, neither the parent ligand nor its complexes
with transition metals, Au, Cu, Fe, Pt and Pd, have been tested
for antimalarial activity. In this paper we report the evaluation of
the activity of such systems. In particular, we employ control
experiments that evaluate whether the assumption of active
‘complex’ idea is a sensible one.
2. Results
2.1. Antimalarial Testing
As part of examining the roles of metals in this study it was
important to first determine the background activities of the
transition metals of interest. The ions investigated in this study
included Cu2+14–16, Fe3+9.14.15, Au3+ and Pt2+ (with terpyridyl).17–19
The toxic effect of each of the metals was determined using their
chloride salts. These results can be seen in Table 1.
With the exception of the platinum salt, the toxicities of the
metals are quite low, and as one might expect in a biological
system, the toxicity increases in the order Fe3+ < Cu2+ < Au3+ <
Pt2+. With these values established it was decided that the metals
would have minimal toxic effect at concentrations of 0.5 µM (as
free metals in the growth medium).
The second part of this study was aimed at determining
whether or not having such a significant metal concentration in
the growth medium would potentiate the activity of the ligand.
In these experiments it was anticipated that the terpyridyl ligand
would form a 1:1 complex with the specific metals. Terpyridyl,
alone, showed an IC50 of 1.0 µM against the 3D7 strain of malaria.
The activities of the different metal background solutions are
reported in Table 2.
A notable result is that of terpyridyl with free iron. The activity
is much weaker than that observed for the ligand alone (1.0 µM, a
more than ten-fold reduction in activity) and therefore suggests
that iron is antagonistic towards the activity of the ligand. This is
likely due to complexation of free iron by terpyridyl which either
prevents its mode of action or alters uptake of the ligand or its
transportation into the parasite. Since the other metals do not
inhibit the activity to such an extent it seems logical to suggest
that the complex formed in situ did in fact prevent the
antimalarial mode of action by reducing its transportation into
the parasite. This is possibly due to the relatively high effective
charge density associated with the terpyridyl-iron(III) complex.
The ligand also shows reduced activity in the presence of free
gold(III), IC50 2.3 µM, although it is not as pronounced as found
in the case of iron (III). This could be due to the larger size of the
gold (III) ion, leading to a lower effective charge density. Free
copper and platinum, both having charges of 2+, in this study
demonstrated no observable effect on the activity of terpyridyl.
Importantly these results have three potential implications.
First, it suggests that the mode of action of these ligands does not
involve the formation of a toxic metal complex in situ. If this were
the case, one would expect a rise in activity with an increase in
background metal concentration (as observed in antibacterial
studies).15 Second, the ligands’ activity does not depend on the
sequestration of these metals away from the parasite, since the
toxic effect is not reversed by the addition of these free metals.
Third, this lack of reversal also suggests that the mode of action is
not mediated via coordination to a metalloenzyme.20 The free
metals should be as easily complexed as enzyme bound metals
thus decreasing the amount of free ligand available to block the
parasite-enzyme metal sites.
Next, complexes of the ligand with each of the metals were
made. Single crystal X-ray structures were obtained for the
copper21 and iron22 terpyridyl complexes and they are shown in
Figs 1 and 2, respectively. We have also published the redeter-
mined structure of gold(III) terpyridyl chloride.23 The anti-
malarial activities of these terpyridyl complexes are reported in
Table 3.
As seen in Table 3, each of the complexes were found to have a
slightly better activity than terpyridyl as a free ligand (IC50 =
1.0 µM). The terpyridyl-gold(III) demonstrates the highest activ-
ity; approximately three-fold of that seen for the ligand on
its own. If one views these results from the perspective of the
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Table 1 Antimalarial activity of transition metals (against strain 3D7 i).
Metal salt IC50/µM
ii







i The 3D7 is a chloroquine susceptible strain of the malaria parasite.
ii The 3D7 strain of P. falciparum was cultured at 37 °C in RPMI-1640 medium
supplemented with 50 mM glucose, 0.65 mM hypoxanthine, 25 mM Hepes, 0.2 %
(w/v) NaHCO3, 0.048 mg mL
–1 gentamicin, 0.5 % (w/v) Albumax II, and 2–4 %
(v/v) human O+ erythrocytes, under an atmosphere of 3 % CO2, 4 % O2, balance
N2.
iii PdCl2 precipitated out during testing.
Table 2 Activities of ligands in presence of free metals.






i Concentrations of the metal ions were 0.5 µM.
ii The 3D7 strain of P. falciparum was cultured at 37 °C in RPMI-1640 medium
supplemented with 50 mM glucose, 0.65 mM hypoxanthine, 25 mM Hepes, 0.2 %
(w/v) NaHCO3, 0.048 mg mL
–1 gentamicin, 0.5 % (w/v) Albumax II, and 2–4 %
(v/v) human O+ erythrocytes, under an atmosphere of 3 % CO2, 4 % O2, balance
N2.







activity of terpyridyl, it appears as if the metals do little to enhance
the activity of the ligand. Furthermore it suggests that metal
complexation is not essential for terpyridyl to exhibit its anti-
malarial effect. In cancer studies it has predominantly been
suggested that metals are required for terpyridyl to exhibit
activity,18,19,24 although a few papers have shown that terpyridyl
and some derivatives have similar or even higher anticancer
activity than their complexes.25–27 It is often the case in literature
studies that the free ligands are not tested for any intrinsic activity.
These results can also be viewed from the perspective of the
metals. For each of the metals the activity has been increased
significantly. A comparison of the activities of the metal salts and
the terpyridyl-metal complexes is shown in Table 4.
The increase in efficacy is most pronounced for iron(approxi-
mately 30 000-fold), followed by gold (approximately 78-fold),
copper (approximately 68-fold) and platinum (approximately
six-fold). This observation concerning the metals is quite possibly
due to their enhanced transportation into the parasite upon
complexation. No direct measurement of the transportation (or
uptake) of the metals was performed. It has, however, been
demonstrated previously that ligands are capable of facilitating
the transport of metal ions into the parasite.9 Thus it could well
be that the ligand allows more of the metal ions to reach their
active site(s) in the parasite.
It is interesting to note that the results are open to interpreta-
tion from either the ligand perspective (which suggests only a
marginal increase in activity) or from the metals’ perspective
(which then suggests a significant increase in activity). If the
exact modes of action of the ligand, the metals and the complexes
were all known, one could perhaps determine which of these
aspects holds more significance. It is of course quite possible as
well that they all act via totally different mechanisms. It is now a
generally held belief that chloroquine exhibits its antimalarial
effect by inhibiting haemozoin formation; whether it is by inhib-
iting an enzyme which produces haemozoin or by preventing a
spontaneous reaction is debatable.28,29 In light of this, it became
essential to test whether any of our agents demonstrate such
ability. A method devised to establish whether potential
antimalarial compounds are capable of performing this feat has
been reported by Egan et al.30
2.2. -Haematin Inhibition
In these experiments chloroquine was used as a standard. The
ligand was also tested to see if it possibly had the same mecha-
nism as chloroquine. It was suspected that this compound might
demonstrate some ability to inhibit Ä-haematin formation due to
its planar structure. Each of the metal salts and in turn their
complexes was evaluated. The results of these investigations are
presented in Table 5.
As seen in Table 5, the terpyridyl alone does not, however,
seem to operate via an inhibition mechanism. It was found that
the metal salts of iron, gold and platinum were capable of inhib-
iting Ä-haematin formation, while that of copper did not. The
same result was also observed for the metal complexes. This
suggests that the ability to inhibit Ä-haematin formation is inher-
ent to the metals, and not a new property of the ligand-metal
complex. The activity of the free metals may well be derived
from their ability to coordinate to the heme groups via the
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Figure 1 ORTEP diagram of copper(II) terpyridyl complex. The ellip-
soids are shown in 50 % probability.
Figure 2 ORTEP diagram of iron(III) terpyridyl complex. The ellipsoids
are shown in 50 % probability.
Table 4 Comparison of the activities of metals and their complexes with
terpyridyl.
Metal salt IC50/µM Complex IC50/µM
CuCl2 35.2 [Cu(terpyridyl)Cl]Cl 0.52
FeCl3 20 × 10
3 Fe(terpyridyl)Cl3 0.63
HAuCl4 23.5 [Au(terpyridyl)Cl]Cl2 0.30




Table 5 Results of Ä-haematin inhibition tests.











i A sample of haemin and NaOH was heated to 70 °C. To this solution was added
firstan acetate buffer solution (pH 5) followed by HCl both pre-incubated at 70 °C.
After stirring for two hours in a temperature-controlled bath, the test tube was
placed on ice for five minutes.
ii A (–) sign implies that Ä-haematin did not form.
iii A (+) sign confirms the formation of Ä-haematin.
propionic functional groups and thus create a form of aggrega-
tion.
These results contrast, however, with other reported platinum
pyridyl complexes. Egan et al.31 suggested that the ability of
these complexes to inhibit Ä-haematin formation could be attrib-
uted to their self-aggregating behaviour, a property likely due to
the planar nature of the ligand-metal complexes. Our results,
however, imply that the Ä-haematin inhibiting properties of any
complexes of iron, gold or platinum, may be due to the metals’
inherent ability to exhibit this action, and not in fact due to the
combination of ligand(s) and metal, as has been reported.
Interestingly the results here also imply that ligands which do
not inhibit Ä-haematin can have this property conferred on them
by metals such as iron, gold and platinum. It confirms the view
that in general ligands can act via different mechanisms from
their corresponding complexes and furthermore that ligands in
the complex form may only be responsible for increasing the
transport (and uptake) of these toxic metals into the parasite. The
activity observed for many complexes may in fact be more a
direct result of the properties of the metal centre.
It should be noted that copper did not demonstrate any ability
to inhibit Ä-haematin formation, neither as the free metal nor in
complex form and yet the terpyridyl-copper complex still shows
higher activity than the free metal. Unfortunately we have no ex-
planation at this time as to why copper and its associated
complex behave in this way.
3. Discussion
This is the first apparent report of the antimalarial activity of
both terpyridyl and its complexes with the metal ions of copper,
iron, gold, and platinum. In order to study the relationship
between the ligands and metals, several experiments were per-
formed. The background activity of each metal was measured.
Their toxicities ranged from 2.4 µM (platinum) to 20 mM
(iron).With these values established, the relationship between
the activities of terpyridyl and the free metal concentrations in
solution was investigated. It was found that with the exception
of iron, the free metal concentration had neither an antagonistic
nor synergistic effect on the antimalarial activity of the ligands.
High concentrations of free iron were antagonistic toward the
activity of terpyridyl (ten-fold reduction of the IC50 to approxi-
mately 10 µM). The metal-ligand complexes were successfully
synthesized and these complexes showed activity similar to that
of the ligand alone. All activities were in the sub-micromolar
range (0.1–1 µM).
As a secondary study the ability of each of the compounds to
inhibit Ä-haematin formation was investigated. While terpyridyl
showed no ability to inhibit Ä-haematin formation, it was revealed
that Ä-haematin inhibition was intrinsic to the metals iron, gold,
platinum and palladium (results not shown) but not copper. It
was also found that all of the complexes of terpyridyl, with the
exception of that of copper, inhibited Ä-haematin formation.
Thus it is apparent that the complexes of terpyridyl, and the
ligand itself, might well exert their toxic effects by different
mechanisms. Unusually our study demonstrates the possibility
that ligands serve to enhance the activity of the metals, an idea
which could be viewed as somewhat opposite to the conven-
tional perspective that metals increase the activities of ligands.
4. Experimental
All solvents and reagents were obtained from Acros, Aldrich,
Fluka, Merck or Alfa-Aesar. Unless otherwise stated, these were
used without further purification. Solvents (CH3CN and DMF)
were dried according to the methods in Vogel.32 All other solvents
were used without drying. Thin-layer chromatography (TLC)
was conducted on aluminium-backed, pre-coated silica gel
plates (Merck, silica gel 60, 20 cm × 20 cm). Column chromatog-
raphy was performed with silica gel 60 (Merck, particle size
0.040–0.063 mm). Proton NMR spectra were recorded at 298 K at
300 MHz on a Varian Unity Inova spectrometer; carbon
NMR spectra were recorded at 75 MHz with the same instru-
ment under the same conditions. Instances where proton and
carbon NMR spectra were recorded at 400 MHz, a Varian Oxford
spectrometer or a Bruker Advance spectrometer were used, at an
operating temperature of 298 K. NMR spectra recorded at
600 MHz were performed under the same condition using a
Bruker Ultrashield spectrometer. Chemical shifts are reported in
parts per million (ppm) and refer to the respective deuterated
solvents as reference, CDCl3 (
1H 7.24 ppm, 13C 77.0 ppm),
d6-DMSO (
1H 2.49 ppm, 13C 39.5 ppm) and D2O (
1H 4.79 ppm,
13C ppm referenced to CH3CN). Infrared spectra were collected
at 293 K by attenuated total reflection (ATR) using a Perkin Elmer
Universal ATR Sampling Accessory attached to a Spectrum
100 FT-IR Spectrometer. Wave numbers are reported in units
of cm–1. All melting points are uncorrected. Mass spectra were re-
corded using a Bruker micrOTOF-Q II Electron Spray Ionization
(ESI) Mass Spectrometer (MS).
[Pt(terpyridyl)Cl)]Cl.2H2O
33
Potassium chloroplatinate(II) (0.100 g, 0.241 mmol) was
dissolved in H2O (5 mL). Solid 2,2’:6’,2’’-terpyridine (0.056 g,
0.24 mmol) was then added to this solution followed by further
H2O (2 mL). The orange solution was then stirred under reflux
overnight. The reaction mixture was then cooled, any particu-
late matter filtered and the solvent removed under reduced
pressure. The resulting solid was then dissolved in a minimum
amount of H2O and the product precipitated out by the addition
of HCl (conc. approx. 10 drops). The bright orange product was
filtered off and dried in a vacuum desiccator (0.042 g, 33 %).Mp
>300 °C. ÇH (400 MHz, DMSO-d6) 8.89 (dd, J=1.5 Hz, J=5.5 Hz,
2H), 8.64 (m, 5H), 8.51 (td, J=8.0 Hz, J=1.5 Hz, 2H), 7.95 (m, 2H).
°C (100 MHz, DMSO-d6) 158.3, 154.4, 151.3, 142.7, 142.1, 129.2,
125.9, 124.5. I.R. (åmax/cm
–1) 3297, 3031, 1604, 1476, 1451, 1401, 1314,
1249, 1091, 1030, 779, 721, 593, 546, 521, 461. Calculated for
PtC15H11N3Cl
+m/z = 463.0289. Found: m/z = 463.0282 [M].
[Au(terpyridyl)Cl]Cl2.3H2O
34
2,2’:6’,2’’-Terpyridine (0.067 g, 0.29 mmol) was added to a solu-
tion of HAuCl4.H2O (0.100 g, 0.294 mmol) in H2O (7.5 mL). This
was followed by the addition of HCl (1 M, 375 µL, 0.375 mmol).
The solution formed a yellow precipitate. The pH was then
adjusted to between 3 and 5 by adding NaOH (1 M, 240 µL,
0.240 mmol) giving an orange-red solution with a yellow precipi-
tate. The reaction mixture was refluxed overnight dissolving
most of the precipitate. After hot filtration, the solvent was
removed and the product recrystallized from H2O (0.090 g,
53 %). Mp 245–250 °C (decomp.). H (400 MHz, DMSO-d6) 8.77
(dd, J=1.5 Hz, J=5.0 Hz, 2H), 8.71 (d, J=8.0 Hz, 2H), 8.49 (d, J=8.0
Hz, 2H), 8.15 (m, 3H), 7.60 (m, 2H). ÇC (100 MHz, DMSO-d6)
151.8, 151.5, 146.8, 141.5, 139.7, 126.0, 122.8, 122.7. I.R. (åmax/cm
–1)
3306, 3010, 1602, 1476, 1449, 1401, 1322, 1249, 1089, 1028, 772, 761,
656, 542, 514, 441. Calculated for AuC15H11N3Cl2
+m/z = 499.9996.
Found: m/z = 499.9978 [M].[Cu(terpyridyl)Cl]Cl35
2,2’:6’,2’’-Terpyridine (0.118 g, 0.506 mmol) was dissolved in
methanol (20 mL) and added to a solution of CuCl2.2H2O
(0.084 g, 0.493 mmol) in methanol (10 mL). The terpyridine
solution was added to the copper(II) chloride solution resulting
in a colour change from light to dark green, followed by the
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formation of a green precipitate. The solution was stirred for
ten min and then left in a freezer for three days. The product, a
dark green powder, was filtered off and recrystallized from
water to afford dark green crystals of the paramagnetic product
(0.139 g, 75 %). Mp >300 °C. I.R. (åmax cm
–1) 3338, 3215, 1631, 1595,
1562, 1489, 1428, 1407, 1302, 776, 737, 648, 625, 437, 408. Calcu-
lated for CuC15H11N3Cl
+m/z = 330.9938. Found: m/z = 330.9936
[M]–Fe(terpyridyl)Cl3
36
2,2’:6’,2’’-Terpyridine (0.100 g, 0.430 mmol) was dissolved in
methanol (5 mL) and added to a solution of FeCl3.6H2O (0.111 g,
0.411 mmol) in methanol (15 mL). The terpyridine solution was
added to the iron(III) chloride solution, resulting in a colour
change from yellow to red, followed by the formation of a yellow
precipitate. The solution was stirred for one hour at room
temperature and filtered. The product was recrystallized from
water to afford amber crystals of the paramagnetic product
(0.122 g, 75 %). Mp >300 °C. I.R. (åmax cm
–1) 3075, 1596, 1574, 1475,
1444, 1317, 1244, 1155, 1096, 1021, 780, 733, 650, 512, 415. Calcu-
lated for FeC15H11N3Cl2
+ m/z = 358.9679. Found: m/z = 358.9678 [M].
[Pd(terpyridyl)Cl]Cl.3H2O from PdCl2
37
Palladium(II) chloride was dissolved in H2O (10 mL) and HCl
(32 %, 3.00 mL, 31.5 mmol) and heated to reflux. The reaction
mixture became clear red and was left for a further 45 min. The
warm solution was filtered and a solution of 2,2’:6’,2’’-ter-
pyridine (0.120 g, 0.514 mmol) in methanol (10 mL) was added
dropwise to the filtrate. The newly formed peach-coloured
precipitate was filtered off and the pH of the filtrate adjusted to
between 4.5 and 5 using NaOH (2 M). The solution was again
filtered and the filtrate left until yellow-orange crystals formed
(0.045 g, 19 %).Mp >300 °C. ÇH (400 MHz, DMSO-d6) 8.72 (dd,
J=1.5 Hz, J=5.5 Hz, 2H), 8.64 (m, 5H), 8.46 (td, J=8.0 Hz, J=1.5
Hz, 2H), 7.88 (m, 2H). °C (100 MHz, DMSO-d6) 158.0, 154.6, 152.0,
142.8, 142.6, 128.9, 125.4, 124.5. I.R. (åmax cm
–1) 3307, 3016, 1601,
1448, 1400, 1320, 1247, 1088, 1027, 774, 719, 657, 566, 514, 440.
Calculated for Pd(C15H11N3)Cl
+m/z = 373.9676. Found: m/z =
373.9675 [M].
4.1. Parasite Culture
The 3D7 strain of P. falciparum was cultured at 37 °C in
RPMI-1640 medium supplemented with 50 mM glucose,
0.65 mM hypoxanthine, 25 mM Hepes, 0.2 % (w/v) NaHCO3,
0.048 mg mL–1 gentamicin, 0.5 % (w/v) Albumax II, and 2–4 %
(v/v) human O+ erythrocytes, under an atmosphere of 3 % CO2,
4 % O2, balance N2.
4.2. Parasite Viability Dose-Response Assays
Culture-derived parasitized erythrocytes were mixed with
fresh culture medium and erythrocytes to yield a 2 % parasitemia,
2 % haematocrit suspension and distributed in microlitre plates
at 100 µL/well. Serial dilutions of test drug in culture medium
were prepared in quadruplicate wells in a separate plate and
transferred to the parasite plate to yield a final volume of
200 µL/well. The plates were incubated at 37 °C for 48 hours and
parasite viability in each well measured by the colorimetric
determination of parasite lactate dehydrogenase activity. All
experiments were performed in triplicate.
4.3. Inhibition of -Haematin Formation Assays
A sample of haemin (15 mg, 0.023 mmol) was placed in a test
tube with NaOH (0.1 M, 3 mL). This mixture was heated to 70 °C.
To this solution was added first an acetate buffer solution
(12.9 M, pH 5, 1.75 mL) followed by HCl (1 M, 0.30 mL) both
pre-incubated at 70 °C. After stirring for two hours in a tempera-
ture-controlled bath, the test tube was placed on ice for five
minutes. In the study by Egan et al.30 Ä-haematin was found to
form within 30 min at 60 °C; however, here it was found that the
formation of Ä-haematin was only complete after two hours at
70 °C. Once cooled the contents of the test tubes were trans-
ferred to vials, and centrifuged at 6000 rpm for five minutes. The
supernatant was decanted, and the remaining solid was shaken
with deionized water (8 mL) and centrifuged again at 6000 rpm
for five minutes. The solid was washed in this way three times
following which, while still wet, it was analysed using an ATR
infrared spectrophotometer (no difference was found whether
the sample was left to dry on the spectrophotometer, usually
within a few minutes, or if it was dried in a desiccator prior to
infrared analysis). This control experiment was used to confirm
Ä-haematin formation under the reaction conditions. The effect
of each compound was determined by adding three equivalents
to the test tube prior to the addition of the acetate buffer solution.
In each run a negative inhibition control (haemin alone) and a
positive inhibition control (a reaction mixture containing three
equivalents of chloroquine phosphate) were used. The forma-
tion of Ä-haematin may be determined by the appearance of two
peaks on the infrared spectrum of solid residue, one at 1660 cm–1
and one at 1207 cm–1.30
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